首页|类器官培养体系下肺腺癌细胞标志物表征与表皮生长因子受体靶向药物敏感性

类器官培养体系下肺腺癌细胞标志物表征与表皮生长因子受体靶向药物敏感性

扫码查看
目的 对肺腺癌细胞形成的肺癌类器官结构与相关标志物进行表征,探讨对其表皮生长因子受体(EGFR)靶向药物敏感性。方法 对常用肺腺癌细胞系A549(EGFR野生型)和H1975(EGFR T790M/L858R)进行肿瘤类器官培养,观测肺癌类器官的形成、形态和增殖;通过HE染色,对形成的肺癌类器官进行微组织结构表征,采用免疫组织化学检测肺癌相关标志物甲状腺转录因子-1(TTF-1)、细胞角蛋白(CK7)、增殖指数(Ki-67)的表达情况并与传统二维培养情况对比;同时采用免疫荧光法检测A549和H1975类器官N-钙黏蛋白(N-cadherin)空间分布和表达情况;对A549和H1975形成的肺癌类器官进行一代与三代靶向药吉非替尼和奥希替尼的药敏试验,通过3D-glo法对ATP进行定量分析,以药物作用剂量为横坐标,细胞活力值为纵坐标,用GraphPad Prism9对数据进行非线性拟合曲线分析,评估药物敏感性。组间比较选取两个独立样本的Student's t test检验,多组数据间比较选取方差分析。结果 肺腺癌细胞A549和H1975分别在7 d和5 d形成平均直径50 μm的类器官球体结构;HE染色显示微结构,二维肺癌细胞与其形成的类器官标志物表达不尽相同;经靶向药物处理后,A549类器官对吉非替尼及奥希替尼都不敏感,而H1975肺癌类器官对吉非替尼呈现耐药对奥希替尼呈现敏感。吉非替尼组A549类器官半数抑制浓度(IC50)高于H1975类器官,差异有统计学意义(1。08 µmol/L比0。50 µmol/L,t=9。90,P<0。05)。奥希替尼组A549类器官IC50高于H1975类器官,差异有统计学意义(1。04μmo1/L比0。01 µmol/L,t=26。78,P<0。05)。结论 表皮生长因子受体(T790M/L858R)突变的肺腺癌细胞H1975形成的肺腺癌类器官较野生型A549形成的肺腺癌类器官对三代TKI药物奥希替尼具有高敏感性。
Characterization of lung adenocarcinoma cell markers and sensitivity to epidermal growth factor receptor targeting drugs in an organoid culture system
Objective To characterize the structure and related markers of lung cancer-like organs formed by lung adenocarcinoma cells and to conduct a preliminary study on their sensitivity to epidermal growth factor receptor(EGFR)-targeted drugs.Methods Tumor organoid cultures of the commonly used lung adenocarcinoma cell lines A549(EGFR wild-type)and H1975(EGFR T790M/L858R)were per-formed to observe the formation,morphology,and proliferation of lung cancer organoids.The expression of TTF-1,CK7 and Ki-67 was detected by immunohistochemistry and compared with the traditional two-di-mensional culture.The spatial distribution and expression of N-cadherin in A549 and H1975 organoids were detected by immunofluorescence at the same time.The drug sensitivity tests of the first and third gen-eration targeted drugs gefitinib and osimertinib were carried out on lung cancer organs formed by A549 and H1975.The ATP was quantitatively analyzed by 3D-glo method.The data were analyzed by non-linear fit-ting curve with GraphPad Prism9 using the drug action dose as the abscissa and the cell viability value as the ordinate.Student's t test test was used for data comparison between two independent samples,and ANOVA between multiple-group.Results Lung adenocarcinoma cells A549 and H1975 formed organoid spheres with an average diameter of 50 µm at 7 and 5 days,respectively.HE staining showed microstruc-tures,and two-dimensional lung cancer cells did not express the same markers as the organoids they formed.After targeted drug treatment,A549 organs were not sensitive to gefitinib and osimertinib,while H1975 lung cancer organs were resistant to gefitinib and sensitive to osimertinib.The A549 organoid half maximal inhibitory concentration(IC50)was significantly higher in gefitinib than H1975(1.08 µmol/L vs.0.50 µmol/L,t=9.90,P<0.05).The A549 IC50 was significantly higher in osimertinib than H1975(1.04 μmol/L vs.0.01 µmol/L,t=26.78,P<0.05).Conclusion Lung adenocarcinoma organoids formed by H1975(T790M/L858R)mutation showed high sensitivity to the three-generation TKI drug osim-ertinib compared with wild-type A549.

Tumor organoidsEpidermal growth factor receptorAdenocarcinoma of lungTumor markersDrug sensitivity

于艳丽、李彦佼、房艳华、王若雨、梁珊珊

展开 >

辽宁省乳腺及消化肿瘤分子标志物高通量筛选及靶向药物转化重点实验室,大连大学附属中山医院肿瘤中心,大连 116001

大连理工大学生物工程学院,大连 116024

肿瘤类器官 表皮生长因子受体 肺腺癌 肿瘤标志物 药物敏感性

国家自然科学基金项目大连市科技局高层次人才创新支持计划-尖端和领军人才项目大连市中医药科学研究计划项目

821728222021RD0222Z11004

2024

中华实验外科杂志
中华医学会

中华实验外科杂志

CSTPCD
影响因子:0.759
ISSN:1001-9030
年,卷(期):2024.41(8)